Abstract: A user host device privately controls a shared remote process that executes in a remote device, in which respective public keys between the user host device and the shared remote process are exchanged through an intermediary device, the user host device validates the process public key based on current and previous nonce values, and sends to the remote process a double-encrypted process command, and the remote process double-decrypts the process command, executes the process command, and then returns a double-encrypted response to the user host device which decrypts and validates the response. Trust between the user host device and the remote process is established by the user host device verifying a remote process response, and the trust is maintained by chaining each session nonce with the previous session nonce, without the knowledge of the intermediary process host device.

Abstract: Switchmode DC-DC power converters using one or more non-Silicon-based switching transistors and a Silicon-based (e.g. CMOS) controller are disclosed. The non-Silicon-based switching transistors may comprise, but are not necessarily limited to, III–V compound semiconductor devices such as gallium arsenide (GaAs) metal-semiconductor field effect transistors (MESFETs) or heterostructure FETs such as high electron mobility transistors (HEMTs). According to an embodiment of the invention, the low figure of merit (FoM), ?FET, of the non-Silicon-based switching transistors allows the converters of the present invention to be employed in envelope tracking amplifier circuits of wireless devices designed for high-bandwidth technologies such as, for example, EDGE and UMTS, thereby improving the efficiency and battery saving capabilities of the wireless devices.

Abstract: The invention provides methods for determining a prognosis for survival for a cancer patient. One method involves (a) measuring a level of a TUCAN in a neoplastic cell-containing sample from the cancer patient, and (b) comparing the level of TUCAN in the sample to a reference level of TUCAN, wherein a low level of TUCAN in the sample correlates with increased survival of the patient. Another method involves (a) measuring a level of TUCAN in a neoplastic cell-containing sample from the cancer patient, and (b) classifying the patient as belonging to either a first or second group of patients, wherein the first group of patients having low levels of TUCAN is classified as having an increased likelihood of survival compared to the second group of patients having high levels of TUCAN.